: Innoviva Completes Acquisition of La Jolla Pharmaceutical Aug BURLIN (ID )
(RTTNews) - Innoviva Inc. (INVA) agreed to acquire La Jolla Pharmaceutical Co. (LJPC). It will pay $5.95 per share for La Jolla, representing a premium of approximately 70% to the 30-day volume
Friday, Septem: 218 218 respm Brief in Support of Motion Fri 09/13 3:46 PM BRIEF in Support filed by LA JOLLA PHARMA, LLC, LA JOLLA PHARMACEUTICAL COMPANY, THE GEORGE WASHINGTON UNIVERSITY re217 MOTION for Partial Summary Judgment (CHEVALIER, CHARLES) NOTICE TO COUNSEL: Counsel is advised that pursuant to Local Civil Rule 5.3(c)(2)
The US Patent and Trademark Office abused its discretion when it rejected La Jolla Pharma LLC's application for a method of treating a
La Jolla Pharma, LLC. Pursuant to the GW License, GW exclusively licensed to us certain intellectual property rights relating to GIAPREZA, including the
La Jolla Pharmaceutical Company's main competitors include Oncopeptides, Ascendis Pharma, IDEAYA Biosciences and Sirnaomics US.
La Jolla Pharmaceutical Company Contact: Michael Hearne Chief Financial Officer La Jolla Pharmaceutical Company (858) . Related Links.
LA JOLLA PHARMACEUTICAL : Chardan Suspends Coverage on La Jolla Pharmaceutical at Buy Rating With $15 Price Target : MT LA JOLLA PHARMACEUTICAL : Chardan Adjusts La Jolla Pharmaceutical's Price Target to $15 From $20, Keeps at Buy : MT
Pharmaceuticals, Orphan Therapeutics LLC, ESP Pharma Inc, PharmaIN Corporation, Baxter International Inc, La Jolla Pharmaceutical Company
Comments
Thanks and keep writing